Despite clinical success, cell and gene therapy pipelines are stunted. The core issue is a broken business model, where therapies are difficult to distribute globally and profitably. A scalable manufacturing platform is the key to enabling profitability, which in turn fuels reinvestment into new therapies.

Rion found that culturing stem cells in a lab to force division leads to rapid DNA damage, as cells are not designed for this artificial environment. This damage created inconsistent exosome products, making large-scale, uniform manufacturing from stem cells unfeasible and prompting a search for a more stable source.

Manufacturing induced pluripotent stem cells (iPSCs) is a highly manual, 'artisanal process' dependent on the subjective skill of individual scientists. This 'magic hands' bottleneck is a major barrier to scaling personalized therapies. Cellino's strategy is to automate these steps with AI and lasers to solve this core challenge.

The manufacturing process fundamentally alters a cell therapy's properties. This creates a conundrum: starting with expensive, fully-automated systems is often unfeasible for early trials, but switching to automation later is risky. The high burden of proving the new process yields an equivalent product can stall late-stage development.

For live cell therapies, the manufacturing process fundamentally shapes the biological product. Teams often rush to scale production, focusing on yield and cost. Instead, they should first fully understand how the process impacts cell potency and function to avoid effectively scaling the wrong biology.

Unlike autologous therapies where one batch treats one patient, a single batch of an allogeneic therapy can treat thousands. This scalability advantage creates a higher regulatory bar. Authorities demand exceptional robustness in the manufacturing process to ensure consistency and safety across a vast patient population, making the quality control challenge fundamentally different and more rigorous.

A 'healthy tension' exists between research teams, who want to continually iterate on a therapy's design, and manufacturing teams, who need a finalized process to scale production for trials. Knowing precisely when to 'lock down' the design is a critical, yet difficult, decision point for successful commercialization.

Resolution Therapeutics' CEO warns that manufacturing process changes cannot wait for pivotal trials in cell therapy. The drug product used in a Phase 1/2 study must be highly comparable to the final commercial version to avoid extremely costly delays and extensive comparability studies later in development.

Unlike traditional biologics with consistent inputs, cell therapy success is dictated by the highly variable quality of patient cells. Heavily pretreated patients yield cells that behave unpredictably, meaning a standard process will inevitably produce a variable product. This fundamental challenge is often underestimated in process development.